A new simultaneous double immunostaining method has been optimized to localize the DNA synthesis marker bromodeoxyuridine (BrdU) and calcitonin gene-related peptide (CGRP) in endocrine cells of Bouin's-fixed, paraffinembedded rat lung. Nuclease pre-treatment before immunostaining is compatible with optimal tissue morphology and CGRP antigenicity preservation. Nickel-enhanced development of avidin-biotin-peroxidase staining is used to show CGRP immunoreactivity in black and alkaline phospha-1 Introduction In 1982, monoclonal antibodies specific for the thymidine analogue 5'-bromodeoxyuridine (BrdU) were produced and applied for the first time to detect DNA replication immunocytochemically (1). Since then, monoclonal antibodies to BrdU have been used increasingly for proliferation studies (2-5). This new method has been compared with the other techniques available for assessment of cell proliferation (6-8). It has been proposed as a faster, easier, and safer alternative to the [3H]-thymidine technique and has the advantage of giving a better morphological definition (9). BrdU is administered shortly before the removal of the tissue (similarly to the [3H]-thymidine technique). Although the monoclonal antibodies recognize BrdU only on monostranded DNA, so that a DNAdenaturing pre-treatment is required, the immunocytochemical demonstration of the incorporation of BrdU is relatively simple.
double immunostaining of BrdU with another antigen have already been described (9) (10) (11) (12) (13) . A simultaneous double staining method (i.e., one set of staining reactions) would be preferable, but is often prevented by the pre-treatments required for denaturing DNA, which reduce or destroy the antigenicity of the second antigen. Therefore, when double immunolocalization of BrdU and another antigen is intended, a compromise between the optimal conditions for immunocytochemical demonstration of each antigen must be achieved. This applies especially to the fixation and pre-treatment procedures.
Thus far, very few such studies have been carried out with a double immunocytochemical technique on endocrine cells (1415) . The aim of the present study was to set up a simple and reliable double immunocytochemical method for simultaneous demonstration of calcitonin gene-related peptide (CGRP) and BrdU to study the uptake of BrdU by CGRP-immunoreactive cells in the lung of the rat. This involved the optimization of the administration of BrdU, the pre-treatment, and the immunocytochemical methods.
Most of the endocrine cells of the rat lung are known to store CGRP (16) . As with other small regulatory peptides, immunocytochemical demonstration of CGRP requires specific conditions (e.g., concerning fmtion) for preservation of its antigenicity. Among the several fixation protocols reported so far for BrdU immunocytochemistry (1749) . only a few are suitable for immunostaining CGRP and other regulatory peptides. In addition, in double immunostaining, the DNA-denaturing pre-treatment required for BrdU detection can reduce the antigenicity of the endocrine peptide. Most of the proteolytic pre-treatments reported previously (17-21) are too harsh for CGRP, and probably also for other regulatory peptides. Double simultaneous immunocytochemical demonstration can be performed only when the protocol is carefully tailored to make the two staining procedures compatible. The main drawback for this purpose is that the possible staining methods and combinations are restricted. In this study we tested different combinations of pre-treatments and immunohistochemical methods.
Although several embedding protocols can be used for BrdU demonstration (10,22,23), we restricted our tests to paraffinembedded tissue to allow good morphological identification in thin (3-5 pm) sections with a large enough tissue area to permit quantitative assessment. As previous studies using a short pulse of [3H]thymidine had shown very little labeling of endocrine cells in lung (24,25), and since our pilot studies administering BrdU in the drinking water (0.8 mg/ml) gave very inconsistent results, osmotic minipumps cannulated to the jugular vein were used to achieve continuous intravenous administration of BrdU.
Materials and Methods

Animals
Wistar rats (specified pathogen-free, male, 200-250 g, n = 11) were used for the present study. Two animals were kept per cage and were allowed food and water ad libitum. All the experiments were performed in accordance with the UK Animals (Scientific Procedures) Act, 1986.
BrdU Adminzstratzon
Osmotic minipumps (Alzet, model 2ML1; Charles River, Margate, Kent, UK) were used to administer BrdU (Sigma B 5002,7 mglml saline; Sigma, St Louis, MO) continuously. The reported delivery duration is 7 days (10 pllhr). Each pump was filled with 2 ml of the BrdU solution and then implanted subcutaneously into the back of each rat. The jugular vein was exposed and catheterized to one end of the pump. A control animal was implanted with an osmotic minipump filled with saline. After closing the wound with sutures, animals were left for 8 days before being sacrificed.
Processing of the Tissues
The animals were sacrificed by intraperitoneal overdose of sodium pentobarbital. The thorax was opened and the extrathoracic trachea was exposed, the larynx was cut, and a cannula was passed into the trachea. The lungs were distended with Bouin's fluid until they filled the thoracic cavity and the trachea was ligated. The lungs were removed from the animal and immersed in Bouin's fixative for 4 hr. A coronal slice of each lobe at the hilar level was obtained and washed in 30% aqueous ethanol. The tissue was dehydrated through graded alcohols, cleared in xylene, and embedded in paraffin. Non-serial sections (3-5 pm) were cut and mounted on slides coated with poly-Llysine (PLL, P1399, Sigma; MW >350,000) (26).
Antibodies
A rabbit polyclonal antiserum to CGRP (ref 1204) and two commercially available monoclonal antibodies against BrdU Amersham International, Amersham, UK; Dakopatts, Glostrup, Denmark) were used for this study. Both the BrdU antibodies were used to stain lung, gut, trachea, adrenals, and kidney from the same BrdU-treated rats.
Amersham RPN-202 (Clone BU-1). The optimal dilution was found by titration to be 1:12. The originality of this reagent is that the manufacturer has already added nucleases to the antibody solution. In this way, the antibody gave a strong signal with both the avidin-biotinylated peroxidase complex (ABC-peroxidase) and the alkaline phosphatase-anti-alkaline phosphatase (APAAP) methods without need for pre-treatment. The neat immunoglobulin-nucleases mixture must be kept at 4°C. In our experience, this antibody gives stronger staining when the working dilution is freshly prepared.
Dako M-744 (Clone Bu2Oa). T h s monoclonal antibody gave strong and precise staining of the BrdU-containing nuclei when used with the appropriate pre-treatment. Howevcr, smooth muscle fibers were sometimes stained slightly when this antibody was used. The optimal dilution was found to be 1:20 for the ABC-peroxidase method. In our material, with the same protocol, the background staining with this antibody was lower than with the Amersham RPN-202.
Pre-treatment
All the commercially available antibodies to BrdU recognize only the BrdU on monostranded DNA and therefore require acid or enzymatic pretreatment of the sections to denature the nucleic acid. Many combinations of enzyme and acid concentrations were tested in pilot studies. The pretreatment tests were performed only with Dakopatts anti-BrdU monoclonal antibody detected by ABC-peroxidase or the indirect immunofluorescence (IF) method.
Optimal pre-treatment for the Dakopatts M-744 (Bu2Oa) antibody consisted of two steps. First, sections were incubated in 0.05 mglml pepsin (Sigma 6887) in 0.1 M HCI for 20 min at 37°C. After thorough washes in PBS (phosphate-buffered saline: 0.01 M Na2HP04lKH2P04 buffer, pH 7.4, and 0.15 M NaCI), a further incubation in nucleases was performed for 20 min at 37". The nuclease solution was either (a) 10 Ulml EcoRI (Amersham T.1040Y) and 10 Ulml Exonuclease 111 (Amersham T.2170Y) diluted in EcoRI assay buffer (100 mM Tris-HC1 pH 7.5, 7 mM MgC12, 50 mM NaCI, 7 mM 2-mercaptoethanol. 0.01% bovine serum albumin), or (b) deoxyribonuclease I (Sigma EC 3.1.21.1), 100 pglml in the same working buffer. This pre-treatment was used for demonstration of BrdU incorporation with avidin-biotin and immunofluorescence techniques (see below), both in single and double protocols.
The Amersham RPN-202 (clone BU-1) antibody does not require the pre-treatment step because the solution provided by the company already contains nucleases.
Double Immunostaining
Double simultaneous immunostaining for CGRP and BrdU was carried out by means of simultaneous peroxidase-anti-peroxidase (PAP) detected by 3,3'-diaminobenzidine tetrahydrochloride (DAB) with nickel enhancement (27) and alkaline phosphatase-anti-alkaline phosphatase (APAAP) (28, 29) . In our pilot studies we also succeeded with three other double staining combinations: First, we showed CGRP with ABC-peroxidase and, after localization and photography of the positive cells, BrdU was demonstrated with nickel-enhanced PAP. Second, we applied successively ABC-peroxidase for CGRP and indirect immunofluorescence for BrdU. Finally, we combined immunogold-silver staining (IGSS) (30) for CGRP and ABC-peroxidase for BrdU. Although these combinations have some advantages, they are not ideal for quantitative studies. For this reason, we chose to develop further the PAP-APAAP double stain. The following protocol was carried out. All the steps were performed at room temperature (2O'C) except when stated otherwise.
Protocol.
1. De-wax in inhibisol and rehydrate through graded alcohols.
Peroxidase Development to Give a Black Endproduct. The peroxidase was revealed by immersing slides in 0.05% 3,3'-diaminobenzidine in 0.1 M sodium acetatelacetic acid buffer, pH 6.0, containing 2.5% ammonium nickel sulfate, 0.2% P-D-glucose, 0.04% ammonium chloride, and 0.001% glucose oxidase (27) for 5-10 min.
Sections were not counterstained. The slides were dried at 37"C, cleared briefly in inhibisol, and mounted with DPX.
Controls
The specificity of the antibodies and the method was tested by the following controls: (a) sections from one animal that was given intravenous saline instead of BrdU were stained; (b) omission or replacement of primary incubation steps or secondary antisera; and (c) staining of sections using CGRP antiserum absorbed with rat aCGRP (1-10 nM/ml diluted antiserum) for 16 hr before immunostaining CGRP.
Results
Pilot studies on the optimal means of continuous administration of BrdU showed that only 70% of the animals given the drug by drinking water displayed a positive immunocytochemical signal, and its strength was variable. In the rest, the signal was extremely -Development ofthe Alkaline Phosphate to Give a Red Endproduct.
1. Filter onto the sections the developing mixture consisting of 10 mg naphthol AS-TR (3-hydroxy-2-naphthoic acid 4'-chloro-2'methylanilide) phosphate dissolved in 0.2 ml of dimethyl forma-weak or absent. In contrast, all the animals treated by osmotic minipumps for 7 days Showed BrdU Signal. Regional differences in the distribution of BrdU incorporation were seen in the lungs of about 40% of these rats; in these, the periphery of the organ Original magnification x 310. Bar = 50 ptn, had a higher density of BrdU-positive cells than the center. Both antibodies were used for the staining and also stained nuclei in kidney ( Figure I) , gut, trachea, and adrenals from the same rats.
Pre-treatments
The quality of the staining, the intensity of the background, and the preservation of the morphology of the tissues was highly dependent on the concentration of the pepsin solution and the duration of this enzymatic digestion step. Zble 1 summarizes our results with the different pre-treatments. The optimal compromise between good morphological preservation, strong specific staining, and low background was achieved by using pepsin at a concentration of 0.05 mglml of 0.1 M HCI for 20 min at 37"C, followed by either the nucleases mixture or the DNAse solution. CGRP immunoreactivity was not affected by pepsin treatment when these optimal conditions were used. When higher concentrations and times were applied, the CGRP signal was decreased. Pepsin (0.3 mglml of 0.1 M HCI) applied to the sections for 30 min at 37°C gave completely negative results for CGRP and the morphology of the sections was greatly damaged. When this treatment was reduced to 5 min, CGRP immunoreactivity could still be found but the morphology was modified, albeit to a lesser extent than with the longer treatment. Pre-treatment with 2 M HCI (30 min, 37°C) did not affect CGRP immunostaining but was not enough to show clear BrdU staining. The morphology of the tissue with this acidic non-enzymatic pre-treatment was better than with the enzymatic ones. For the Amersham antibody, no further pre-treatment apart from the nucleases already provided with the antibodies was applied. The results with this antibody were comparable to those obtained with the optimal pepsin plus nucleases pre-treatment using the Dako antiserum.
Double Staining
The two antibodies that we have used for this study were suitable for double staining techniques. for CGRP and APAAP for BrdU] proved valid for the double immunocytochemical demonstration of both antigens. The sensitivity for BrdU detection in terms of primary antiserum dilution was higher for ABC and APAAP than for IE With the simultaneous APAAPPAP-nickel method, double immunostained cells were shown in different and well-contrasted colors (Figures 2 and 3) . Nuclei that had incorporated BrdU were stained in bright red by means of the APAAP method, whereas CGRP was demonstrated by the black deposit given by the DAB with nickelenhancement reaction for peroxidase. The high sensitivity of the APAAP method somewhat increased the slight nonspecific reactivity of the second layer (anti-mouse immunoglobulin) with rat immunoglobulin. giving a higher background, especially in the blood vessel lumina. Although the sharp signal of the specific BrdU reaction in the nuclei stood out very clearly from the background staining, even in the case of a weaker BrdU immunoreaction, careful obsermtion with a high-magnification objective was required for quantitative studies to avoid missing some weakly BrdU-stained cells and to distinguish isolated CGRP-IR cells from unspecific CGRP-positive alveolar macrophages. Reapplication of the APAAP second and third layers was essential to obtain good BrdU staining. The slides were dried at 37°C to avoid the dehydration through alcohols that removes some of the endproduct of the alkaline phosphatase reaction. Some of the very fine details of cell morphology were, for this reason, slightly affected. For demonstration of the double staining in monochrome pictures, a comparison between the staining pattern of the nuclei in a given field taken with and without a red filter (Wratten, W-30) was necessary (Figures 4 and 5) .
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Discussion
The results presented here have shown that a double immunocytochemical method can be optimized to localize simultaneously the proliferation marker BrdU and a peptide of endocrine cells. Our results also suggest that nuclease pre-treatment before BrdU immunostaining helps to improve the staining when Bouin's fluidfixed, paraffin-embedded tissues are used, at least in the case of the lung. The results also confirm that good immunostaining for BrdU can be achieved with the type of fixative used for regulatory peptide immunocytochemistry.
Two different monoclonal antibody clones have been used, BU-1 and Bu2Oa. For our final protocol, the Amersham BU-1 antibody was chosen because the standardization of the double immunoreaction was easier. The two-step Pre-treatment required by Bu20a added variability to the staining pattern, especially because of the pepsin digestion. Although BU-1 seems to be the best antibody for quantitative studies, when good morphological detail and low background are prerequisites, the Bu2Oa clone, with low pepsin and nucleases pre-treatment, seems to be the appropriate-protocol, and a staining method that permits dehydration through alcohols is recommended.
The first report of the effect of nucleases on BrdU immunoreactivity was by Gonchoroff et al. (31) . These authors showed the ability of the clone BU-1 antibody to react with incorporated BrdU in ethanol-fixed cells when DNAse was present in the BU-1 culture fluid. More recently, a protocol for nuclease pre-treatment of paraffin-embedded sections was briefly reported by Dinjens et al. (32) . These authors report the absence of background after treatment with pepsin plus Exonuclease 111. Our experiments with the nuclease pre-treatments also showed an improvement in the staining, especially in the signaknoise ratio, with both BU-1 and Bu2Oa clones, for Bouin's-fixed material. Schutte et al. (33) suggest that the efficiency of the nuclease digestion will vary depending on the fixative used. The most common fixatives for regulatory peptides (e.g., CGRP) are p-benzoquinone and formaldehyde-based fixatives (34) . In previous immunocytochemical studies on the CGRPproducing cells of the rat lung Bouin's fluid was used successfully (35) (36) (37) . Although most of the BrdU immunocytochemical studies have been carried out with tissues or cells fixed in ethanol or Carnoy's fluid, there have been several studies on the effect of different fixatives and pre-treatments on the immunohistochemical demonstration of BrdU in waxor plastic-embedded tissues (10, 17, 19, 33, 38) . Most of them mention Bouin's fluid as avalid fixative for BrdU. Veronese et al. (19) , working with paraffin-embedded tumors, report optimal preservation of the BrdU antigenicity when Bouin's fluid is used. In their hands, tissues fixed in Bouin's solution and treated with acid and thermal DNA denaturation methods did not show any improvement in BrdU reactivity after pepsin digestion. In contrast, Schutte et al. (33) , studying a wide range offixatives, did not find BrdU labeling in Bouin's-fixed tissues unless digestion with pepsin was performed. In fact, their optimal concentration of pepsin is almost the same as ours. Our results also coincide with thein conceming the need of enzymatic pre-treatment to achieve a good quality of staining. Nevertheless, many of the studies published about the effect of fixatives and pre-treatments on BrdU immunocytochemisuy differ strikingly in some of the conclusions reported. It is likely that the optimal fixation and pretreatment may be antibody-clone dependent and tissue specific. Dombrowicz et al. (39) report tissue-specific differences in the BrdU signal using the same fixation. In conclusion, when a proliferation study involving BrdU immunocytochemistry is intended, it is critical to do a pilot study to optimize the tissue, antibody, and me*od.
Among the four double staining methods tested in the pilot studies, we preferred the PAP-APAAP method because the staining technique involving fluorescence would require continuous switching from the transmitted to the fluorescence mode of the microscope. The combination involving immunogold-silver staining is good for morphological studies but requires a carefully controlled development that is difficult to achieve when a large number of slides are processed. The non-enhanced followed by nickel-enhanced PAP combination has problems due to blackening of the original brown DAB reaction product, or detection of residual peroxidase, when the nickel-enhancing solution is used in the second staining. The APAAP + PAP simultaneous protocol reported in the present study proved to be very useful, both for easy recognition of double immunostained cells and for quantification. The red endproduct yielded by the naphthol AS-TR phosphate and hexazotized new fuchsin contrasts highly with the black staining of the diaminobenzidine enhanced with metallic nickel. Variations of this APAAP-peroxidase double staining have already been published for double immunostaining with BrdU, although using the blue endproduct for alkaline phosphatase (13, 19) or using the APAAP reaction for the other antigen instead of the BrdU (9.15). To our knowledge, this is the first report of simultaneous double immunostaining for BrdU and another antigen, all previously reported double immunostaining being carried out sequentially although visualized simultaneously. Application of the different layers as mixed solutions considerably reduces the time required for double immunostaining. This was possible because the pre-treatment selected was mild enough to permit the preservation of CGRP antigenicity and results were particularly good with the BU-1 antibody, which does not need pepsin digestion of the sections. The APAAP technique is highly sensitive (29) ensuring optimal visualization of the nuclei that have incorporated the drug. The advantage of the BU-1 antibody for the quantitative assessment of proliferation is clear in that it avoids one of the main sources of variability of the BrdU immunostaining and of damage to other antigens, i.e., the pepsin pre-treatment. Nevertheless, a certain degree of variability between staining batches is also present with this APAAP-PAP technique, as with any staining technique, and must be taken into account when statistical analysis is performed.
There are very few studies on the proliferation of peptidesecreting (endocrine) cells using BrdU as a marker of proliferative activity. Only two of them (14,lS) use double immunocytochemistry to detect both antigens (BrdU and the endocrine peptide). Davidson et al. (40) studied the regeneration of pancreatic betacell populations by means of BrdU immunocytochemistry but detected the beta-cells only by their location within the islets. In the present study, a method for simultaneous detection of BrdU and CGRP immunoreactivity is shown and applied to the endocrine cells of the lung. It seems likely that this method will be useful for the study of proliferation of a much wider range of cell types.
